HepaRegeniX: Revolutionizing Liver Regeneration with Innovative Therapy
July 13, 2024, 9:35 pm
In a groundbreaking development, HepaRegeniX, a clinical stage company based in Tuebingen, Germany, has successfully secured €15 million in Series C funding to propel the clinical development of HRX-215, a novel regenerative therapy aimed at treating acute and chronic liver diseases. Led by Vesalius Biocapital IV, with the participation of existing investors Novo Holdings, Boehringer Ingelheim Venture Fund (BIVF), and High-Tech Gründerfonds (HTGF), this funding round signifies a significant milestone for HepaRegeniX.
The appointment of Elias Papatheodorou as Chief Executive Officer, transitioning from his previous role as Chair of the Board, along with the addition of Dr. Linda Greenbaum as Chief Medical Officer, marks a strategic move by HepaRegeniX to strengthen its leadership team and drive forward its mission to revolutionize liver regeneration therapy.
HRX-215, a small molecule inhibitor targeting Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4), has shown promising results in unlocking the regenerative capacity of hepatocytes, offering a potential boost to liver regeneration in patients with liver metastases, primary liver tumors, and those in need of liver transplants. The completion of a Phase I trial and publication of results in the prestigious journal Cell underscore the potential of HRX-215 to transform the landscape of liver disease treatment.
Fabienne Roussel, Partner at Vesalius Biocapital IV, expressed excitement about supporting HepaRegeniX in its next phase of clinical development, highlighting the urgent need for a treatment that can induce liver regeneration in patients facing liver damage and tumors. The addition of Dr. Linda Greenbaum, with her extensive experience in clinical development and translational medicine, further strengthens HepaRegeniX's position in advancing the clinical development of HRX-215.
Elias Papatheodorou emphasized the significance of the new funding and the expanded leadership team in driving HepaRegeniX towards its goal of delivering much-needed therapy to patients suffering from liver diseases. With a focus on advancing HRX-215 through Phase II trials and beyond, the company aims to improve outcomes for patients globally and make a meaningful impact in the field of liver health.
HepaRegeniX's innovative approach, rooted in the discovery of MKK4 as a key regulator of liver regeneration, has the potential to transform the treatment landscape for liver diseases. With a strong investor backing and a dedicated team of experts, HepaRegeniX is poised to lead the way in revolutionizing liver regeneration therapy and offering hope to patients in need of effective treatment options.
The appointment of Elias Papatheodorou as Chief Executive Officer, transitioning from his previous role as Chair of the Board, along with the addition of Dr. Linda Greenbaum as Chief Medical Officer, marks a strategic move by HepaRegeniX to strengthen its leadership team and drive forward its mission to revolutionize liver regeneration therapy.
HRX-215, a small molecule inhibitor targeting Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4), has shown promising results in unlocking the regenerative capacity of hepatocytes, offering a potential boost to liver regeneration in patients with liver metastases, primary liver tumors, and those in need of liver transplants. The completion of a Phase I trial and publication of results in the prestigious journal Cell underscore the potential of HRX-215 to transform the landscape of liver disease treatment.
Fabienne Roussel, Partner at Vesalius Biocapital IV, expressed excitement about supporting HepaRegeniX in its next phase of clinical development, highlighting the urgent need for a treatment that can induce liver regeneration in patients facing liver damage and tumors. The addition of Dr. Linda Greenbaum, with her extensive experience in clinical development and translational medicine, further strengthens HepaRegeniX's position in advancing the clinical development of HRX-215.
Elias Papatheodorou emphasized the significance of the new funding and the expanded leadership team in driving HepaRegeniX towards its goal of delivering much-needed therapy to patients suffering from liver diseases. With a focus on advancing HRX-215 through Phase II trials and beyond, the company aims to improve outcomes for patients globally and make a meaningful impact in the field of liver health.
HepaRegeniX's innovative approach, rooted in the discovery of MKK4 as a key regulator of liver regeneration, has the potential to transform the treatment landscape for liver diseases. With a strong investor backing and a dedicated team of experts, HepaRegeniX is poised to lead the way in revolutionizing liver regeneration therapy and offering hope to patients in need of effective treatment options.